FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006676880> ?p ?o ?g. }

• W3006676880 abstract "Periorbital and orbital cellulitis are infections of the tissue anterior and posterior to the orbital septum, respectively, and can be difficult to differentiate clinically. Periorbital cellulitis can also progress to become orbital cellulitis. Orbital cellulitis has a relatively high incidence in children and adults, and potentially serious consequences including vision loss, meningitis, and death. Complications occur in part due to inflammatory swelling from the infection creating a compartment syndrome within the bony orbit, leading to elevated ocular pressure and compression of vasculature and the optic nerve. Corticosteroids are used in other infections to reduce this inflammation and edema, but they can lead to immune suppression and worsening infection.To assess the effectiveness and safety of adjunctive corticosteroids for periorbital and orbital cellulitis, and to assess their effectiveness and safety in children and in adults separately.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2020, Issue 3); Ovid MEDLINE; Embase.com; PubMed; Latin American and Caribbean Health Sciences Literature Database (LILACS); ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on 2 March 2020.We included studies of participants diagnosed with periorbital or orbital cellulitis. We excluded studies that focused exclusively on participants who were undergoing elective endoscopic surgery, including management of infections postsurgery as well as studies conducted solely on trauma patients. Randomized and quasi-randomized controlled trials were eligible for inclusion. Any study that administered corticosteroids was eligible regardless of type of steroid, route of administration, length of therapy, or timing of treatment. Comparators could include placebo, another corticosteroid, no treatment control, or another intervention.We used standard methodological procedures recommended by Cochrane.The search yielded 7998 records, of which 13 were selected for full-text screening. We identified one trial for inclusion. No other eligible ongoing or completed trials were identified. The included study compared the use of corticosteroids in addition to antibiotics to the use of antibiotics alone for the treatment of orbital cellulitis. The study included a total of 21 participants aged 10 years and older, of which 14 participants were randomized to corticosteroids and antibiotics and 7 participants to antibiotics alone. Participants randomized to corticosteroids and antibiotics received adjunctive corticosteroids after initial antibiotic response (mean 5.13 days), at an initial dose of 1.5 mg/kg for three days followed by 1 mg/kg for another three days before being tapered over a one- to two-week period. We assessed the included study as having an unclear risk of bias for allocation concealment, masking (blinding), selective outcome reporting, and other sources of bias. Risk of bias from sequence generation and incomplete outcome data were low. The certainty of evidence for all outcomes was very low, downgraded for risk of bias (-1) and imprecision (-2). Length of hospital stay was compared between the group receiving antibiotics alone compared to the group receiving antibiotics and corticosteroids (mean difference (MD) 4.30, 95% confidence interval (CI) -0.48 to 9.08; 21 participants). There was no observed difference in duration of antibiotics between treatment groups (MD 3.00, 95% CI -0.48 to 6.48; 21 participants). Likewise, preservation of visual acuity at 12 weeks of follow-up between group was also assessed (RR 1.00, 95% CI 0.82 to 1.22; 21 participants). Pain scores were compared between groups on day 3 (MD -0.20, 95% CI -1.02 to 0.62; 22 eyes) along with the need for surgical intervention (RR 1.00, 95% CI 0.11 to 9.23; 21 participants). Exposure keratopathy was reported in five participants who received corticosteroids and antibiotics and three participants who received antibiotic alone (RR 1.20, 95% CI 0.40 to 3.63; 21 participants). No major complications of orbital cellulitis were seen in either the intervention or the control group. No side effects of corticosteroids were reported, although it is unclear which side effects were assessed.There is insufficient evidence to draw conclusions about the use of corticosteroids in the treatment of periorbital and orbital cellulitis. Since there is significant variation in how corticosteroids are used in clinical practice, additional high-quality evidence from randomized controlled trials is needed to inform decision making. Future studies should explore the effects of corticosteroids in children and adults separately, and evaluate different dosing and timing of corticosteroid therapy." @default.
• W3006676880 created "2020-02-24" @default.
• W3006676880 creator A5012580978 @default.
• W3006676880 creator A5027203858 @default.
• W3006676880 creator A5030417997 @default.
• W3006676880 creator A5056643856 @default.
• W3006676880 creator A5060067565 @default.
• W3006676880 creator A5074098140 @default.
• W3006676880 creator A5077121384 @default.
• W3006676880 date "2021-04-28" @default.
• W3006676880 modified "2023-10-18" @default.
• W3006676880 title "Corticosteroids for periorbital and orbital cellulitis" @default.
• W3006676880 cites W1858720576 @default.
• W3006676880 cites W1965876232 @default.
• W3006676880 cites W1992275978 @default.
• W3006676880 cites W2004450907 @default.
• W3006676880 cites W2032341011 @default.
• W3006676880 cites W2050136041 @default.
• W3006676880 cites W2054250996 @default.
• W3006676880 cites W2066544439 @default.
• W3006676880 cites W2076457536 @default.
• W3006676880 cites W2077778904 @default.
• W3006676880 cites W2078670072 @default.
• W3006676880 cites W2103274521 @default.
• W3006676880 cites W2105434315 @default.
• W3006676880 cites W2118084360 @default.
• W3006676880 cites W2132391410 @default.
• W3006676880 cites W2132493481 @default.
• W3006676880 cites W2143774329 @default.
• W3006676880 cites W2145344990 @default.
• W3006676880 cites W2147372379 @default.
• W3006676880 cites W2156098321 @default.
• W3006676880 cites W2160408047 @default.
• W3006676880 cites W2171678537 @default.
• W3006676880 cites W2314442979 @default.
• W3006676880 cites W2395492617 @default.
• W3006676880 cites W2412386651 @default.
• W3006676880 cites W246286872 @default.
• W3006676880 cites W2553747192 @default.
• W3006676880 cites W2601106311 @default.
• W3006676880 cites W2609109646 @default.
• W3006676880 cites W2781509367 @default.
• W3006676880 cites W2781632684 @default.
• W3006676880 cites W2791286089 @default.
• W3006676880 cites W2802032718 @default.
• W3006676880 cites W2809486551 @default.
• W3006676880 cites W2888257110 @default.
• W3006676880 cites W2914805281 @default.
• W3006676880 cites W2989716526 @default.
• W3006676880 cites W3000668231 @default.
• W3006676880 cites W3006676880 @default.
• W3006676880 cites W4233215763 @default.
• W3006676880 cites W4234982337 @default.
• W3006676880 cites W4256570019 @default.
• W3006676880 cites W4294215472 @default.
• W3006676880 cites W81317408 @default.
• W3006676880 doi "https://doi.org/10.1002/14651858.cd013535.pub2" @default.
• W3006676880 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8092453" @default.
• W3006676880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33908631" @default.
• W3006676880 hasPublicationYear "2021" @default.
• W3006676880 type Work @default.
• W3006676880 sameAs 3006676880 @default.
• W3006676880 citedByCount "3" @default.
• W3006676880 countsByYear W30066768802021 @default.
• W3006676880 countsByYear W30066768802023 @default.
• W3006676880 crossrefType "journal-article" @default.
• W3006676880 hasAuthorship W3006676880A5012580978 @default.
• W3006676880 hasAuthorship W3006676880A5027203858 @default.
• W3006676880 hasAuthorship W3006676880A5030417997 @default.
• W3006676880 hasAuthorship W3006676880A5056643856 @default.
• W3006676880 hasAuthorship W3006676880A5060067565 @default.
• W3006676880 hasAuthorship W3006676880A5074098140 @default.
• W3006676880 hasAuthorship W3006676880A5077121384 @default.
• W3006676880 hasBestOaLocation W30066768802 @default.
• W3006676880 hasConcept C126322002 @default.
• W3006676880 hasConcept C141071460 @default.
• W3006676880 hasConcept C168563851 @default.
• W3006676880 hasConcept C2777238321 @default.
• W3006676880 hasConcept C2779171459 @default.
• W3006676880 hasConcept C535046627 @default.
• W3006676880 hasConcept C71924100 @default.
• W3006676880 hasConceptScore W3006676880C126322002 @default.
• W3006676880 hasConceptScore W3006676880C141071460 @default.
• W3006676880 hasConceptScore W3006676880C168563851 @default.
• W3006676880 hasConceptScore W3006676880C2777238321 @default.
• W3006676880 hasConceptScore W3006676880C2779171459 @default.
• W3006676880 hasConceptScore W3006676880C535046627 @default.
• W3006676880 hasConceptScore W3006676880C71924100 @default.
• W3006676880 hasIssue "4" @default.
• W3006676880 hasLocation W30066768801 @default.
• W3006676880 hasLocation W30066768802 @default.
• W3006676880 hasLocation W30066768803 @default.
• W3006676880 hasOpenAccess W3006676880 @default.
• W3006676880 hasPrimaryLocation W30066768801 @default.
• W3006676880 hasRelatedWork W1975184308 @default.
• W3006676880 hasRelatedWork W1980189266 @default.
• W3006676880 hasRelatedWork W1980666300 @default.
• W3006676880 hasRelatedWork W1996292932 @default.
• W3006676880 hasRelatedWork W2032705424 @default.
• W3006676880 hasRelatedWork W2081814204 @default.

• next